Akums Drugs IPO Details
IPO Date	July 30, 2024 to August 1, 2024
Listing Date	August 6, 2024
Face Value	₹2 per share
Issue Price Band	₹646 to ₹679 per share
Issue Price Final	₹679 per share
Lot Size	22 Shares
Sale Type	Fresh Capital-cum-Offer for Sale
Total Issue Size	2,73,68,143 shares
(aggregating up to ₹1,856.74 Cr)
Fresh Issue	1,00,37,708 shares
(aggregating up to ₹680.99 Cr)
Offer for Sale	1,73,30,435 shares of ₹2
(aggregating up to ₹1,175.75 Cr)
Employee Discount	₹64.00
Issue Type	Bookbuilding IPO
Listing At	BSE, NSE
Share Holding Pre Issue	14,73,56,280 shares
Share Holding Post Issue	15,73,71,007 shares
Akums Drugs and Pharmaceuticals IPO Reservation
Akums Drugs and Pharmaceuticals IPO offers total 2,73,68,151 shares. Out of which 2,03,43,188 (74.33%) allocated to QIB, 81,37,276 (29.73%) allocated to QIB, 40,68,637 (14.87%) allocated to NII, 27,12,424 (9.91%) allocated to RII and 1,22,05,912 (44.60%) allocated to Anchor investors.

Investor Category	Shares Offered	Maximum Allottees
QIB Shares Offered	2,03,43,188 (74.33%)	NA
NII (HNI) Shares Offered	40,68,637 (14.87%)	NA
Retail Shares Offered	27,12,424 (9.91%)	1,23,292
Employee Shares Offered	2,43,902 (0.89%)	NA
Total Shares Offered	2,73,68,151 (100.00%)	
Investor Category Reservations
Application Category	Maximum Bidding Limits	Bidding at Cut-off Price Allowed
Only RII	Up to Rs 2 Lakhs	Yes
Only sNII	Rs 2 Lakhs to Rs 10 Lakhs	No
Only bNII	Rs 10 Lakhs to NII Reservation Portion	No
Only employee		Yes
Employee + RII/NII	
Employee limit: (In certain cases, employees are given discount if bidding amount is upto Rs. 2 lakhs)
If applying as RII: Upto Rs. 2 lakhs
If applying as NII: sNII > Rs. 2 lakhs and upto Rs. 10 lakhs and bNII > Rs. 10 lakhs
Yes for Employee and RII/NII
Akums Drugs IPO Anchor Investors Details
Akums Drugs IPO raises ₹828.78 crore from anchor investors. Akums Drugs IPO Anchor bid date is July 29, 2024. Akums Drugs IPO Anchor Investors list

Bid Date	July 29, 2024
Shares Offered	1,22,05,912
Anchor Portion Size (In Cr.)	828.78
Anchor lock-in period end date for 50% shares (30 Days)	September 1, 2024
Anchor lock-in period end date for remaining shares (90 Days)	October 31, 2024
Akums Drugs IPO Timeline (Tentative Schedule)
Akums Drugs IPO opens on July 30, 2024, and closes on August 1, 2024.

IPO Open Date	Tue, Jul 30, 2024
IPO Close Date	Thu, Aug 1, 2024
Tentative Allotment	Fri, Aug 2, 2024
Initiation of Refunds	Mon, Aug 5, 2024
Credit of Shares to Demat	Mon, Aug 5, 2024
Tentative Listing Date	Tue, Aug 6, 2024
Cut-off time for UPI mandate confirmation	5 PM on Thu, Aug 1, 2024
Akums Drugs IPO Lot Size
Investors can bid for a minimum of 22 shares and in multiples thereof.  The following table depicts the minimum and maximum investment by Individual Investors (Retail) and HNI in terms of shares and amount.

Application	Lots	Shares	Amount
Retail (Min)	1	22	₹14,938
Retail (Max)	13	286	₹1,94,194
S-HNI (Min)	14	308	₹2,09,132
S-HNI (Max)	66	1,452	₹9,85,908
B-HNI (Min)	67	1,474	₹10,00,846
Akums Drugs IPO Promoter Holding
Sanjeev Jain, Sandeep Jain, and Akums Master Trust are the company's promoters.
Promoter Holding Pre Issue	84.94%
Promoter Holding Post Issue	
Note : The value will be calculated using Equity Dilution = Share Holding Pre Issue - Share Holding Post Issue

About Akums Drugs & Pharmaceuticals Ltd.
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.

The company primarily provides end-to-end solutions for product development and manufacturing as well as research and development (R&D) of formulations, preparation and submission of regulatory dossiers in the Indian and global markets and other testing services. The company is also engaged in the manufacture and sale of branded drugs and active pharmaceutical ingredients (APIs).

As a CDMO, the company manufactures a wide range of dosage forms including tablets, capsules, liquid medicines, vials, ampoules, blow-filled closures, topical preparations, eye drops, dry powder injections and gummy bears, to name a few.

The company has produced a total of 4,025 commercialized formulations in over 60 dosage forms. In the financial year 2023, the company manufactured formulations for 26 of the top 30 pharmaceutical companies in India in terms of revenue. For its CDMO business, the company operates 10 manufacturing units with a cumulative production capacity of 49.21 billion units annually (as of September 30, 2023).

The company plans to expand its production capacity with two additional production units for its CDMO business to be commissioned in FY 2025. Some of its production facilities have been accredited by various global regulatory bodies such as the European Good Manufacturing Practice (EU-GMP), the World Health Organization Good Manufacturing Practice (WHO-GMP) and the United States National Sanitation Foundation (US NSF).

As of September 30, 2023, Akums Drugs and Pharmaceuticals had a total of 16,463 employees, including 7,211 full-time employees and 9,252 contract employees.

Company Financials
Akums Drugs and Pharmaceuticals Limited Financial Information (Restated Consolidated)
Akums Drugs and Pharmaceuticals Limited's revenue increased by 13.81% and profit after tax (PAT) dropped by -99.19% between the financial year ending with March 31, 2024 and March 31, 2023.

Period Ended	31 Mar 2024	31 Mar 2023	31 Mar 2022
Assets	3,516.37	3,266.53	3,069.05
Total Income	4,212.21	3,700.93	3,694.52
Profit After Tax	0.79	97.82	-250.87
Net Worth	709.50	717.19	621.98
Reserves and Surplus	861.01	868.70	787.79
Total Borrowing	491.56	536.97	357.95
Amount in ₹ Crore
Key Performance Indicator (KPI)
KPI	Values
ROE	0.11%
ROCE	3.37%
Debt/Equity	0.69
RoNW	-0.57
PAT Margin	0.02%
Price to Book Value	13.69
Check Akums Drugs IPO Peer Comparison here.
Objects of the Issue (Akums Drugs IPO Objectives)
The Company proposes to utilize the Net Proceeds towards the funding of the following objects:

Repayment/ prepayment of indebtedness of the company and its Subsidiaries;
Funding incremental working capital requirements of the company;
Pursuing inorganic growth initiatives through acquisitions; and
General corporate purposes.
Akums Drugs IPO Review
[Dilip Davda]  The company is enjoying a leadership in CDMO segment and has many blue-chip domestic as well as global pharma companies as its loyal customers. If we consider the restated performance excluding put call liabilities, the IPO is priced at a P/E of 29.79 based on FY24 earnings. The issue appears fully priced. Investors may park funds for the medium to long term. Read detail review...

Akums Drugs and Pharmaceuticals IPO Subscription Status (Bidding Detail)
The Akums Drugs and Pharmaceuticals IPO is subscribed 63.44 times on August 1, 2024 6:19:08 PM (Day 3). The public issue subscribed 20.8 times in the retail category, 90.09 times in the QIB category, and 42.1 times in the NII category. Check Day by Day Subscription Details (Live Status)

Category	Subscription (times)	Shares Offered	Shares bid for
QIB	90.09	81,37,276	73,31,17,770
NII	42.1	40,68,637	17,13,07,510
    bNII (bids above ₹10L)	47.43	27,12,425	12,86,49,664
    sNII (bids below ₹10L)	31.45	13,56,212	4,26,57,846
Retail	20.8	27,12,424	5,64,23,114
Employee	4.14	2,43,902	10,08,810
Total	63.44	1,51,62,239	96,18,57,204
Total Application : 23,44,029

Akums Drugs IPO Prospectus
  ›  Akums Drugs IPO DRHP
  ›  Akums Drugs IPO RHP
  ›  Anchor Investors in Akums Drugs IPO
  ›  Akums Drugs IPO Final Prospectus
Akums Drugs IPO Listing Details
Listing Date	August 6, 2024
BSE Script Code	544222
NSE Symbol	AKUMS
ISIN	INE09XN01023
Final Issue Price	₹679 per share
BSE Listing Group	B (Rolling)
Pre-Open Session - NSEPre-Open Session - BSE

Listing Day Trading Information
Price Details	NSE SME	NSE SME
Final Issue Price	₹679.00	₹679.00
Open	₹725.00	₹725.00
Low	₹724.50	₹725.00
High	₹797.45	₹797.50
Last Trade	₹796.35	₹796.25